Partners
AI-DRIVEN SOLUTIONS FOR PHARMA PARTNERS
BENEFITS FOR PHARMACEUTICAL PARTNERS
Develop novel therapeutics from a de-risked pipeline of targets and hits across cardiovascular, neurological, and rare diseases.
Initiate target discovery for new therapeutic programs using one of the only phenotypic drug discovery platforms available with unique clinical data.
Improve clinical study design and strategy to support existing assets leveraging our proven machine learning models for patient stratification and biomarker discovery.
Diverse, Growing, Strategic
Our innovations and efforts are driving validation and proprietary value at every stage of drug discovery for the world’s largest pharmaceutical and clinical brands. BioSymetrics is also building a growing ecosystem of experimental partners and platforms to validate predictions across model systems.
THERAPEUTIC AREA FOCUS & TARGET DISCOVERY PROGRAMS
Cardiometabolic
Familial Dilated Cardiomyopathy
Heart Failure (HFpEF)
Hypertrophic Cardiomyopathy
Myofibrillar Myopathy
Atherosclerosis
Non-Alcoholic Steatohepatitis
Neuroscience
Epilepsy
Parkinson’s Disease
Amyotrophic Lateral Sclerosis (ALS)
Migraine
Post-COVID-19 Anosmia
Rare Diseases
Charcot-Marie-Tooth Disease
Marfan Disease
Alport Disease
Polycystic Kidney Disease
(ADPKD)
Interested in Partnering?
We seek partners with a desire to transform drug discovery, to help advance our drug discovery programs or embark on new programs in cardiac, neurodegenerative and rare diseases.
We are highly collaborative experts in machine learning, data science and drug discovery. Let’s chat.